Context Therapeutics presents preclinical data on CT-95

Context Therapeutics (CNTX) announced preclinical and translational data regarding the Company’s clinical asset, CT-95, a mesothelin x CD3 TCE was presented at the American Association for Cancer Research, AACR, Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, IL. “There is a high unmet need for effective treatments in mesothelin expressing cancers. CT-95 is affinity tuned and avidity enhanced to concentrate drug activity within the tumor microenvironment,” said Martin Lehr, Chief Executive Officer of Context. “We believe these preclinical and translational data support the clinical strategy to target mesothelin expressing cancers, including pancreatic, ovarian, and mesothelioma. We recently dosed the first patient in our Phase 1 clinical trial of CT-95 and expect to share initial clinical data in mid-2026.”